Previous 10 | Next 10 |
PERSIST-AVR study results presented at American Association for Thoracic Surgery Annual Meeting LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, presented the first data from the Perceval ® Sutureless Implant Versus Standard-Aortic Valve ...
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the publication of a new study in the International Journal of Bipolar Disorders 1 that showed adding Vagus Nerve Stimulation Therapy (VNS Therapy ® ) to treatment as usual (TAU) si...
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will present new findings from its Perceval ® Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study at the 100 th Annual Meeting of the American Association of...
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20 at 10:50 a.m. Eastern Time. The discussion will be available to all interest...
Image source: The Motley Fool. LivaNova PLC (NASDAQ: LIVN) Q1 2020 Earnings Call Apr 29, 2020 , 8:00 a.m. ET Operator Continue reading
LivaNova PLC (LIVN) Q1 2020 Results Conference Call April 29, 2020 08:00 AM ET Company Participants Matthew Dodds - Senior Vice President of Corporate Development Damien McDonald - Chief Executive Officer Thad Huston - Chief Financial Officer Melissa Farina - Vice President of ...
The following slide deck was published by LivaNova PLC in conjunction with their 2020 Q1 earnings Read more ...
LivaNova PLC (NASDAQ: LIVN ): Q1 Non-GAAP EPS of $0.33 misses by $0.10 ; GAAP EPS of $0.79 beats by $0.80 . More news on: LivaNova PLC, Earnings news and commentary, Healthcare stocks news, Read more ...
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020. For the first quarter of 2020, worldwide sales from continuing operations were $242.4 million, a decrease of 3.4 percent on a reported basis...
Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned CE Mark approval for E...
News, Short Squeeze, Breakout and More Instantly...
2024-06-23 00:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. ...
2024-06-06 11:00:14 ET Rick Wise from Stifel Nicolaus issued a price target of $70.00 for LIVN on 2024-06-06 09:52:00. The adjusted price target was set to $70.00. At the time of the announcement, LIVN was trading at $53.16. The overall price target consensus is at $69.5...